ADVA
12.8.2021 09:02:11 CEST | Business Wire | Press release
ADVA (FSE: ADV) today introduced its FSP 150-XJ128 , the industry’s first Layer 2 demarcation device that offers an easy route to 25Gbit/s connectivity services. The solution is specifically designed to enable enterprise networks to expand in an easy and cost-effective way. Until now, businesses had to choose between juggling their 10Gbit/s devices or making the expensive leap to 100Gbit/s. With the ADVA FSP 150-XJ128, they can address soaring data demand without using complex modulation techniques or undergoing a costly footprint increase. The solution simply slots into existing network infrastructure and delivers 2.5x the bandwidth at a lower cost per bit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005050/en/
“Our FSP 150-XJ128 is the technology that businesses have been calling for. It empowers them to take the natural next step with zero hassle and without unnecessary expense. For many enterprises, trying to manage rapidly rising bandwidth needs using 10Gbit/s demarcation devices has become a real headache. Yet it doesn’t make economic sense to overhaul their entire system and go all the way to 100Gbit/s. What we’re providing is the ideal stepping stone for secure business growth,” said Christoph Glingener, CTO, ADVA. “Until today, there was no middle ground. Now, businesses can slot our FSP 150-XJ128 into their existing network infrastructure and seize new revenue opportunities.”
The ADVA FSP 150-XJ128 is ideal for 5G sites moving to 25Gbit/s and the perfect choice for preparing cable networks for DOCSIS 4.0 and above. The compact device supports 25Gbit/s Ethernet services with sophisticated OAM capabilities. Optimized for cost-sensitive high-bandwidth edge applications, the ADVA FSP 150-XJ128 features fanless operation and an extended temperature range, removing the need for expensive air-conditioning. With its hardware-assisted synchronization features, it also meets the most stringent timing requirements. Managed by ADVA’s Ensemble Controller and Ensemble Packet Director , the FSP 150-XJ128 gives operations teams the power of intuitive and comprehensive network control.
“What we’re offering businesses is a solution that hits the sweet spot. It enables enterprise networks to handle significantly more workloads and data-hungry applications without major investment or increased complexity. Now there’s a way to meet the bandwidth needs of 5G and cloud computing without complex modulation techniques or breaking the bank,” commented Eli Angel, VP, product line management, ADVA. “As we’ve shown in several customer demos, our simple plug-and-play FSP 150-XJ128 delivers 2.5x the bandwidth in an instant. What’s more, it provides the Layer 2 demarcation and synchronization capabilities that enterprise networks require. Today’s launch marks the start of a new era of 25Gbit/s connectivity and a whole new world of opportunity for businesses.”
Further information on the ADVA FSP 150-XJ128 is available in these slides: https://adva.li/fsp-150-xj128-slides .
Additional details can also be found in this video: https://youtu.be/ikE9quU0gjc .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005050/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
